Literature DB >> 18524834

Properties of subviral particles of hepatitis B virus.

Ning Chai1, Ho Eun Chang, Emmanuelle Nicolas, Ziying Han, Michal Jarnik, John Taylor.   

Abstract

In the sera of patients infected with hepatitis B virus (HBV), in addition to infectious particles, there is an excess (typically 1,000- to 100,000-fold) of empty subviral particles (SVP) composed solely of HBV envelope proteins in the form of relatively smaller spheres and filaments of variable length. Hepatitis delta virus (HDV) assembly also uses the envelope proteins of HBV to produce an infectious particle. Rate-zonal sedimentation was used to study the particles released from liver cell lines that produced SVP only, HDV plus SVP, and HBV plus SVP. The SVP made in the absence of HBV or HDV were further examined by electron microscopy. They bound efficiently to heparin columns, consistent with an ability to bind cell surface glycosaminoglycans. However, unlike soluble forms of HBV envelope protein that were potent inhibitors, the SVP did not inhibit the ability of HBV and HDV to infect primary human hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524834      PMCID: PMC2519590          DOI: 10.1128/JVI.00561-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus.

Authors:  F L Chang; P J Chen; S J Tu; C J Wang; D S Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 2.  Assembly of hepadnaviral virions and subviral particles.

Authors:  D Ganem
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

3.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication.

Authors:  M Chao; S Y Hsieh; J Taylor
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

5.  Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis.

Authors:  V Bruss; K Vieluf
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor.

Authors:  U Klingmüller; H Schaller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Hepatitis B virus and the control of hepatocellular carcinoma.

Authors:  B S Blumberg
Journal:  IARC Sci Publ       Date:  1984

8.  Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein.

Authors:  V Bruss; X Lu; R Thomssen; W H Gerlich
Journal:  EMBO J       Date:  1994-05-15       Impact factor: 11.598

9.  A dramatic shift in the transmembrane topology of a viral envelope glycoprotein accompanies hepatitis B viral morphogenesis.

Authors:  P Ostapchuk; P Hearing; D Ganem
Journal:  EMBO J       Date:  1994-03-01       Impact factor: 11.598

10.  Novel transmembrane topology of the hepatitis B virus envelope proteins.

Authors:  R Prange; R E Streeck
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

View more
  33 in total

Review 1.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Microvesicles and viral infection.

Authors:  David G Meckes; Nancy Raab-Traub
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

3.  Subviral Hepatitis B Virus Filaments, like Infectious Viral Particles, Are Released via Multivesicular Bodies.

Authors:  Bingfu Jiang; Kiyoshi Himmelsbach; Huimei Ren; Klaus Boller; Eberhard Hildt
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 4.  Exosomes in Viral Disease.

Authors:  Monique R Anderson; Fatah Kashanchi; Steven Jacobson
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

5.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

6.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection.

Authors:  Xiaochen Tian; Chao Zhao; Hongguang Zhu; Weimin She; Jiming Zhang; Jing Liu; Lanjuan Li; Shusen Zheng; Yu-Mei Wen; Youhua Xie
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 8.  Host factors involved in hepatitis B virus maturation, assembly, and egress.

Authors:  Reinhild Prange
Journal:  Med Microbiol Immunol       Date:  2012-09-11       Impact factor: 3.402

9.  Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion.

Authors:  Tamako Garcia; Jisu Li; Camille Sureau; Kiyoaki Ito; Yanli Qin; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

10.  A function essential to viral entry underlies the hepatitis B virus "a" determinant.

Authors:  Jessica Salisse; Camille Sureau
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.